Search research articles
Contact Us
Filters
Showing results (431-440 of 504) with videos related to
Page
of 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
The Lancet. Oncology
|
March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Arnon P Kater, Önder Arslan, Fatih Demirkan, et al.
International Journal of Cancer
|
November 18, 2018
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
Nikos Papakonstantinou, Stavroula Ntoufa, Maria Tsagiopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2019
Reply to J. Wang et al
David M Kurtz, Florian Scherer, Michael C Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma
Jan-Michel Heger, Laman Mammadova, Julia Mattlener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Haematologica
|
October 5, 2019
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
Jared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, et al.
Leukemia
|
November 7, 2025
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial
Riccardo Moia, Simone Ragaini, Luciano Cascione, et al.
Page
of 51
Search research articles
Search
Showing results (431-440 of 504) with videos related to
Sort By:
Page
of 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
The Lancet. Oncology
|
March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Arnon P Kater, Önder Arslan, Fatih Demirkan, et al.
International Journal of Cancer
|
November 18, 2018
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
Nikos Papakonstantinou, Stavroula Ntoufa, Maria Tsagiopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2019
Reply to J. Wang et al
David M Kurtz, Florian Scherer, Michael C Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma
Jan-Michel Heger, Laman Mammadova, Julia Mattlener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Haematologica
|
October 5, 2019
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
Jared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, et al.
Leukemia
|
November 7, 2025
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial
Riccardo Moia, Simone Ragaini, Luciano Cascione, et al.
Page
of 51